Use Our Content This story will be republished at no cost (details).
President Donald Trump, armed with the experience of workers seasoned within the methods of the drug trade, unveiled his blueprint to handle sky-high drug costs Friday afternoon, promising that growing trade competitors will assist Americans save on the pharmacy counter.
“Under this administration, we are putting American patients first,” Trump mentioned with Secretary of Health and Human Services Alex Azar by his aspect. Azar, he mentioned, had a mission to “to bring soaring drug prices down to Earth.”
Many of the proposals Trump’s crew can accomplish administratively — and a few are already in movement — however for others, Trump mentioned, he plans to work with Congress.
The administration’s blueprint proposes 50 actions to cut back what Americans pay for medication, together with giving Medicare extra energy to barter drug costs, Azar mentioned.
Azar mentioned he needs to make drug costs extra clear, as properly. For instance, he mentioned the Food and Drug Administration ought to require pharmaceutical firms to reveal medication’ record costs of their direct-to-consumer tv advertisements.
“It’s material and relevant to know if it’s a $50,000 drug or a $100 drug,” Azar mentioned.
Dr. Jeremy Greene, a professor and well being coverage professional at Johns Hopkins Medicine, mentioned he was puzzled by how a lot management the company would have over requiring drug costs as a part of promoting.
“The FDA has had nothing to do with price, especially in advertising,” Greene mentioned. “There have been prominent court cases over whether pharmacies can or cannot advertise based on drug prices.”
Regardless, Trump referred to as the plan “the most sweeping action in history to lower the price of prescription drugs to the American people.”
“We will have tougher negotiations, more competition and much lower prices at the pharmacy counters,” Trump mentioned. “And it will start to take effect very soon.”
Email Sign-Up
Subscribe to KHN’s free Morning Briefing.
On a separate be aware, Trump informed the viewers that “right-to-try is happening,” a nod to congressional efforts to develop entry to experimental drugs for folks with life-threatening situations.
Trump’s proposals goal decreasing the out-of-pocket prices for older Americans enrolled in Medicare — however specialists say that quantities to extra present than substance.
“There’s a difference between reducing the pain people feel associated with out-of-pocket costs at the pharmacy counter and reducing the actual national spend on prescription drugs,” mentioned Allan Coukell, senior director for well being applications on the nonpartisan Pew Charitable Trusts.
While 80 percent of Americans say the price of medication is unreasonable, 1 in four folks report having problem paying for medication, in response to Kaiser Family Foundation polling. And the federal government is paying extra, too. Medicare’s drug spending grew practically 90 p.c from 2006 to 2015, with an annual common progress price of seven.6 p.c, in response to Pew.
During the marketing campaign and his presidency, Trump has used robust language in opposition to the pharmaceutical trade, famously saying the producers are “getting away with murder.” Late Thursday, senior administration officers informed reporters on a name that the plan will cut back the value pharmaceutical firms set for medication.
But when requested about whether or not Medicare will negotiate medication — as Democrats have referred to as for and the president has talked about — administration officers mentioned that lever wouldn’t be pulled.
Instead, Trump’s blueprint requires measures akin to providing free generics to low-income seniors, passing on to shoppers extra of the negotiated financial savings that insurers win, and ensuring Medicare enrollees don’t spiral into the so-called catastrophic section of protection they hit after they pay hundreds of a 12 months for medication.
Leigh Purvis, director of well being providers analysis at AARP Public Policy Institute, mentioned the president’s proposals fail to finally tackle that spending. AARP has lengthy referred to as for Medicare to have the power to barter costs.
“Anything that doesn’t address the list price really is just kind of squeezing the balloon in this world,” Purvis mentioned.
For Medicare sufferers, although, limiting what they pay out-of-pocket could possibly be particularly useful to these taking most cancers medication or different costly therapies, mentioned Stacie Dusetzina, an affiliate professor of well being coverage at Vanderbilt University School of Medicine.
Today, sufferers who pay $5,000 out-of-pocket for prescriptions enter the “catastrophic” class of Medicare protection, and are charged simply 5 p.c of their drug prices. But given the astronomical value of most cancers medication, that may depart sufferers paying $1,000 a month or extra, Dusetzina mentioned.
Medicare sufferers with the lethal most cancers a number of myeloma can spend $14,000 a 12 months out-of-pocket for the drug Revlimid, which prices about $20,000 a month, Dusetzina mentioned.
Trump additionally accused different developed nations of “freeloading” by having fun with the fruits of American innovation — together with medication developed with taxpayer cash or by U.S. firms — with out paying a good value. Because nationwide well being methods in different nations have authority to barter drug prices — and refuse to cowl some medication totally — their residents usually pay a fraction of the costs charged within the United States.
“In some cases, medicines that cost a few dollars in foreign countries cost hundreds of dollars for the same pill” within the United States, Trump mentioned. “It’s unfair, it’s ridiculous and it’s not going to happen any longer. It’s time to end the global freeloading once and for all.”
A spokesman for Doctors Without Borders mentioned Trump has it backward. Instead of elevating drug costs overseas, prices want to come back down in every single place, mentioned Leonardo Palumbo, U.S. advocacy adviser for the group’s entry marketing campaign.
“Other countries aren’t ‘free-riding,’ and lifesaving medicines aren’t more expensive here because they cost less elsewhere,” Palumbo mentioned.
Today, Medicare has restricted energy to barter drug costs, partly as a result of most of the costliest remedies — akin to these for most cancers sufferers — are in a protected class that should be coated, Dusetzina mentioned.
To actually negotiate higher costs, Medicare would wish the liberty to reject some medication fully, Dusetzina added.
But excluding sure costly medication from the Medicare program might depart sufferers in a troublesome place, mentioned Chris Hansen, president of the American Cancer Society’s Cancer Action Network. Patients who need an costly drug would both need to skip it or pay for it themselves, he mentioned.
Azar mentioned Medicare might strain drug firms to maintain costs down in different methods.
“In our drug discount program, if you have a drug in a protected class, it’s almost impossible for drug plans to negotiate and get a discount,” Azar mentioned. “What if we said you only get to be in a protected class if you haven’t raised your price in 18 months?”
Some coverage specialists, although, mentioned Trump’s proposals are principally outdated concepts.
“I don’t think anyone is talking seriously about having Medicare negotiate with drugmakers,” mentioned Tom Bulleit, head of the well being care apply on the D.C. workplace of Ropes & Gray.
Rep. Peter Welch (D-Vt.), who together with Rep. Elijah Cummings (D-Md.) met with Trump on the White House a 12 months in the past to suggest modifications on drug costs, mentioned, “If you listen carefully, you can almost hear the champagne popping in the corporate boardrooms of drug companies across the country.”
David Maris, a pharmaceutical trade analyst for Wells Fargo traders, launched a be aware earlier this month declaring that the elevated social and financial stress on the drug trade is constructing.
“My guess is this is just the beginning,” Maris mentioned.
Trump’s plan contains tackling the rising prices of medicine in Medicare’s Part B program, which pays for medication delivered in physician’s workplaces or hospital outpatient setting — a problem earlier administrations have did not sort out.
While the small print are nonetheless obscure, Trump has referred to as for the costs paid for sure medication underneath Part B — these might embody costly medication for most cancers chemotherapy and rheumatoid arthritis — to be negotiated utilizing the identical ways insurers and pharmacy profit managers use underneath Medicare Part D, which is this system that seniors use for his or her retail pharmaceuticals.
Azar mentioned the administration plans to launch a request for info to assemble enter on modifications to this system.
The Pharmaceutical Research and Manufacturers of America launched an announcement Friday saying it was trying ahead to working with the administration and warning: “While some of these proposals could help make medicines more affordable for patients, others would disrupt coverage and limit patients’ access to innovative treatments.”
Use Our Content This story will be republished at no cost (details).
KHN’s protection of prescription drug improvement, prices and pricing is supported by the Laura and John Arnold Foundation.
[Update: This story was updated at 5:15 p.m. ET on May 11 with further comments from health care industry and policy experts.]
Sarah Jane Tribble: sjtribble@kff.org”>sjtribble@kff.org, @SJTribble
Liz Szabo: lszabo@kff.org”>lszabo@kff.org, @LizSzabo
Related Topics Cost and Quality Health Industry Medicare Pharmaceuticals Drug Costs Out-Of-Pocket Costs Prescription Drugs Trump Administration U.S. Congress src=”http://platform.twitter.com/widgets.js” charset=”utf-8″>